Ai2 Limited, a Manchester, UK-based developer of innovative technology to prevent infection on a wide range of commonly used medical devices like urinary catheters, stents and wound dressings, received a £250,000 investment from MTI Partners.
The investment, which was made through the UMIP Premier Fund, will enable the company to progress the technology platform and seek alliances and partnerships in specific applications, including contact lenses and wound dressings.
Commenting on the financing, Dr. Curtis Dobson, founder and director of Ai2, was quoted as saying: “We are delighted to announce the successful closure of this current round.
“This funding will allow us to build on our successes to date and implement and validate our technology in the hands of partners.
“Clinical infection is a serious problem, and with this investment we can play our part in delivering a new and lasting solution”.
In September 2009, the company received a £100,000 Grant for Research and Development (GRAND), the incentive aimed at helping entrepreneurs and business owners introduce innovative products and processes, including research trials and product testing.